Download PDF
pferde spiegel 2023; 26(03): 145-150
DOI: 10.1055/a-2092-2464
Labor

Pituitary Pars intermedia Dysfunction – ein Update

Carla Axt
› Further Information
    Permissions and Reprints All articles of this category

Bis zu 25% der Pferde über 15 Jahre zeigen eines oder mehrere klinische Anzeichen einer Pituitary Pars intermedia Dysfunction. Damit ist sie die häufigste endokrinologische Erkrankung älterer Pferde und Tierärzte werden entsprechend oft damit konfrontiert.

Publication History

Article published online:
11 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clinics North Am Equine Pract 2011; 27 (01) 93-113
    CrossrefPubMedGoogle Scholar
  • 2 Schott HC. Pituitary pars intermedia dysfunction: Equine Cushingʼs disease. Vet Clinics North Am Equine Pract 2002; 18 (02) 237-270
    CrossrefPubMedGoogle Scholar
  • 3 McFarlane D, Dybdal N, Donaldson M. et al. Nitration and increased-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J. Neuroendocrinol 2005; 17: 73-80
    CrossrefPubMedGoogle Scholar
  • 4 Fortin JS, Hetak AA, Duggan KE. et al. Equine pituitary pars intermedia dysfunction: A spontaneous model of synucleinopathy. Sci Rep 2021; 11: 16036
    CrossrefPubMedGoogle Scholar
  • 5 Miller MA, Pardo ID, Jackson LP. et al. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol 2008; 45: 26-38
    CrossrefPubMedGoogle Scholar
  • 6 Kritchevsky JE. Hypertrichosis Associated with Adenomas of the Pars Intermedia, MSD Manual Veterinary Manual 2022. Online (Letzter Zugriff: 29.06.2023): https://www.msdvetmanual.com/endocrine-system/the-pituitary-gland/hypertrichosis-associated-with-adenomas-of-the-pars-intermedia
    Google Scholar
  • 7 van der Kolk JH, Kalsbeek HC, van Garderen E. et al. Equine pituitary neoplasia: A clinical report of 21 cases (1990–1992). Vet Rec 1993; 133: 594-597
    PubMedGoogle Scholar
  • 8 McFarlane D, Donaldson MT, McDonnell SM. et al. Effects of season and sample handling on measurement of plasma α-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004; 65: 1463-1468
    CrossrefPubMedGoogle Scholar
  • 9 Banse HE, Whitehead AE, McFarlane D. et al. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy. Domest Anim Endocrinol 2021; 76: 106620
    CrossrefPubMedGoogle Scholar
  • 10 Ireland J, McGowan C. Epidemiology of pituitary pars intermedia dysfunction: A systematic literature review of clinical presentation, disease prevalence and risk factors. Vet J 2018; 235: 22-33
    CrossrefPubMedGoogle Scholar
  • 11 McFarlane D, Hill K, Anton J. Neutrophil function in healthy aged horses and horses with pituitary dysfunction. Vet Immunol Immunopathol 2015; 165: 99-106
    CrossrefPubMedGoogle Scholar
  • 12 Miller AB, Loynachan AT, Bush HM. et al. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses. Domest Anim Endocrinol 2021; 74: 106531
    CrossrefPubMedGoogle Scholar
  • 13 Keresztes M, Horváth T, Ocsovszki I. et al. ACTH- and cortisol-associated neutrophil modulation in coronary artery disease patients undergoing stent implantation. PLoS ONE 2013; 8: e71902
    CrossrefPubMedGoogle Scholar
  • 14 de Laat MA, McGowan C, Sillence M. et al. Equine laminitis: Induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Vet J 2010; 42: 129-135
    CrossrefPubMedGoogle Scholar
  • 15 Equine Endocrinology Group. Pituitary Pars Intermedia Dysfunction 2021. Online (Letzter Zugriff: 29.06.2023): https://sites.tufts.edu/equineendogroup
    Google Scholar
  • 16 McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006; 30: 276-288
    CrossrefPubMedGoogle Scholar
  • 17 Pease A, Schott H, Howey E. et al. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction. J Vet Intern Med 2011; 25: 1144-1151
    CrossrefPubMedGoogle Scholar
  • 18 Durham A, McGowan C, Fey K. et al. Pituitary pars intermedia dysfunction: Diagnosis and treatment. Equine Vet Educ 2014; 26: 216-223
    CrossrefGoogle Scholar
  • 19 Rendle D, Doran G, Ireland J. et al. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. Domest Anim Endocrinol 2019; 68: 135-141
    CrossrefPubMedGoogle Scholar
  • 20 Prascend Tablets Pergolide Mesylate. In: Proceedings of the Corrected Freedom of Information Summary, Boehringer Ingelheim Vetmedica, Ingelheim, Germany, 7 September 2011.
    Google Scholar